World-first burn treatment with "absolutely remarkable" results performed at leading Canadian hospital

Contributed by: PR Newswire

Tags

Hamilton-Health-Sci

More Like This

PR Newswire associated0

Kimera® Labs Inc publishes novel brain targeting of exosomes in Nature Scientific Reports

Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered to be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.

Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026

In 2008, GN Corp initiated research with NCRM, Chennai, Tamil Nadu, India on restoring corneal blindness using buccal tissue epithelial cells. An out of the box idea of Dr. Suryaprakash, Urologist from Hyderabad, India in 2012 to apply buccal (oral) mucosal cells to repair stricture-inflicted male urethra, led to a clinical study, which he presented in NCRM NICHE 2017 in Tokyo, kickstarting a collaboration with Dr. Akio Horiguchi, National Defence Medical College, Japan, as they met in EAU in 2018 (Top right picture). Upon confirming successful cell engraftment in urethral stricture pre-clinical models taking help from the Dept. of Medical Engineering of NDMC between 2018~2023, (Bottom, right picture), now in 2025, clinical application has been initiated in Edogawa Hospital, Tokyo. Main picture: BEES-HAUS team after the first clinical transplant in Edogawa Hospital, Tokyo; Dr.Horiguchi (Centre) with Dr.Shojiro Katoh (President, Edogawa Hospital) standing left to him.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

NHS red tape blitz delivers game-changing new cancer treatment

GlobeNewswire associated0

KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering

Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform